论文部分内容阅读
目的探讨小剂量利妥昔单抗治疗难治性特发性血小板减少性紫癜(ITP)临床效果、安全性及经济效果。方法选择我院住院17例难治性ITP患者,采用利妥昔单抗(100mg,每周1次,连用4周),监测治疗前后血常规、血清免疫球蛋白定量和血小板相关抗体。结果治疗后血小板计数为(76.4±58.6)×109/L,治疗有效率为64.7%;随访6~39个月,复发率36.4%,无严重不良反应;治疗成本明显低于标准剂量的利妥昔单抗。结论小剂量的利妥昔单抗是治疗难治性ITP安全、有效药物,价格适中。
Objective To investigate the clinical efficacy, safety and economic effect of low dose rituximab in the treatment of refractory idiopathic thrombocytopenic purpura (ITP). Methods Seventeen patients with refractory ITP were selected in our hospital. Rituximab (100mg once a week for 4 weeks) was used to monitor blood routine, serum immunoglobulin quantitation and platelet-associated antibody before and after treatment. Results After treatment, the platelet count was (76.4 ± 58.6) × 109 / L, the effective rate was 64.7%. The follow-up ranged from 6 to 39 months, the recurrence rate was 36.4%, with no serious adverse reactions. The treatment cost was significantly lower than that of the standard dose Serum monoclonal antibody. Conclusions Low dose rituximab is a safe and effective drug for refractory ITP and is affordable.